# Transdermal delivery of antenatal steroids to promote fetal lung maturation: Proof of principle data from sheep and non-human primate models.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12317452</article-id><article-id pub-id-type="pmid">40751152</article-id>
<article-id pub-id-type="publisher-id">4267</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04267-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Transdermal delivery of antenatal steroids to promote fetal lung maturation: Proof of principle data from sheep and non-human primate models</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Carter</surname><given-names>Sean W. D.</given-names></name><address><email>e0983544@u.nus.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Benetti</surname><given-names>Ay&#x000e7;a Altay</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sia</surname><given-names>Ryan Tze Liang</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Pastorin</surname><given-names>Giorgia</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Erin L.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Seah</surname><given-names>Kay Yi Michelle</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Usuda</surname><given-names>Haruo</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Watson</surname><given-names>Hannah R. S.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kumagai</surname><given-names>Yusaku</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Qin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiawen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Orefice</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bon</surname><given-names>Marianne</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Amin</surname><given-names>Zubair</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Biswas</surname><given-names>Agnihotri</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Tsukasa</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mochii</surname><given-names>Noriyoshi</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Saito</surname><given-names>Yuya</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ikeda</surname><given-names>Hideyuki</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Saito</surname><given-names>Masatoshi</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Choolani</surname><given-names>Mahesh A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Illanes</surname><given-names>Sebasti&#x000e1;n E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Kemp</surname><given-names>Matthew W.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tgyzw49</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution>Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, </institution><institution>National University of Singapore, </institution></institution-wrap>1E Kent Ridge Road NUHS Tower Block, Level 12, Singapore, Singapore </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ns3e792</institution-id><institution-id institution-id-type="GRID">grid.415259.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0625 8678</institution-id><institution>King Edward Memorial Hospital, </institution></institution-wrap>Perth, Australia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tgyzw49</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution>Department of Pharmacy and Pharmaceutical Sciences, </institution><institution>National University of Singapore, </institution></institution-wrap>Singapore, Singapore </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/047272k79</institution-id><institution-id institution-id-type="GRID">grid.1012.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7910</institution-id><institution>Division of Obstetrics and Gynaecology, </institution><institution>University of Western Australia, </institution></institution-wrap>Perth, Australia </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00kcd6x60</institution-id><institution-id institution-id-type="GRID">grid.412757.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0641 778X</institution-id><institution>Centre for Perinatal and Neonatal Medicine, </institution><institution>Tohoku University Hospital, </institution></institution-wrap>Sendai, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00zat6v61</institution-id><institution-id institution-id-type="GRID">grid.410737.6</institution-id><institution-id institution-id-type="ISNI">0000 0000 8653 1072</institution-id><institution>School of Pharmaceutical Sciences, </institution><institution>Guangzhou Medical University, </institution></institution-wrap>Guangzhou, Guangdong China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/019wvm592</institution-id><institution-id institution-id-type="GRID">grid.1001.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 7477</institution-id><institution>School of Medicine and Psychology, </institution><institution>Australian National University, </institution></institution-wrap>Canberra, Australia </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04h7nbn38</institution-id><institution-id institution-id-type="GRID">grid.413314.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9984 5644</institution-id><institution>Department of Obstetrics and Gynaecology, </institution><institution>Canberra Hospital, </institution></institution-wrap>Garran, Australia </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04fp9fm22</institution-id><institution-id institution-id-type="GRID">grid.412106.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0621 9599</institution-id><institution>Department of Neonatology, Khoo-Teck Puat National University Children&#x02019;s Medical Institute, </institution><institution>National University Hospital, </institution></institution-wrap>Singapore, 119228 Singapore </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tgyzw49</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution>Department of Paediatrics, Yong Loo Lin School of Medicine, </institution><institution>National University of Singapore, </institution></institution-wrap>Singapore, Singapore </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03v0qd864</institution-id><institution-id institution-id-type="GRID">grid.440627.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0487 6659</institution-id><institution>Reproductive Biology Program, Center for Biomedical Research and Innovation, Universidad de los Andes, </institution></institution-wrap>Santiago, Chile </aff><aff id="Aff12"><label>12</label>IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04fp9fm22</institution-id><institution-id institution-id-type="GRID">grid.412106.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0621 9599</institution-id><institution>Department of Obstetrics and Gynaecology, </institution><institution>National University Hospital, </institution></institution-wrap>Singapore, Singapore </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05tjjsh18</institution-id><institution-id institution-id-type="GRID">grid.410759.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0451 6143</institution-id><institution>Department of Obstetrics and Gynaecology, </institution><institution>National University Centre for Women and Children (NUWoC), National University Health System, </institution></institution-wrap>Singapore, Singapore </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>452</elocation-id><history><date date-type="received"><day>26</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>7</day><month>7</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Antenatal steroids (ANS) are routinely administered to women at risk of preterm birth to accelerate fetal lung maturation. Despite extensive clinical use, dosing and route of ANS administration remain unoptimized beyond intramuscular (IM) injection. We aimed to undertake a proof-of-principle assessment of transdermal ANS administration for accelerated fetal lung maturation.</p></sec><sec><title>Methods</title><p id="Par2">We formulated and tested a transdermal ANS (betamethasone) patch in ex vivo studies. To confirm in vivo transdermal distribution of the ANS patch, we undertook a 24-h pharmacokinetic study in non-pregnant cynomolgus macaques (NHP). To assess the efficacy of transdermal betamethasone on fetal lung maturation, we used a preterm sheep model of pregnancy comparing postnatal ventilation outcomes. Date mated ewes received either of the following: (i) IM normal saline (Saline Control, <italic>n</italic>&#x02009;=&#x02009;13); (ii) IM ANS (betamethasone) delivery 2 or 8&#x000a0;days post-treatment (2-Day IM ANS, <italic>n</italic>&#x02009;=&#x02009;14; 8-day IM ANS Group, <italic>n</italic>&#x02009;=&#x02009;6); (iii) IM saline&#x02009;+&#x02009;2&#x02009;&#x000d7;&#x02009;transdermal ANS (Betamethasone) patches delivery 2&#x000a0;days post-treatment (2-Day ANS Patch, <italic>n</italic>&#x02009;=&#x02009;10); or (iv) IM saline&#x02009;+&#x02009;2&#x02009;&#x000d7;&#x02009;transdermal ANS (betamethasone) patches replaced with 2&#x02009;&#x000d7;&#x02009;new patches after 48&#x000a0;h, delivery 8&#x000a0;days post-treatment (8-Day ANS Patch, <italic>n</italic>&#x02009;=&#x02009;11). Lambs were delivered at 123&#x02009;&#x000b1;&#x02009;1 dGA (term 150&#x000a0;days), then ventilated for 30&#x000a0;min to assess lung maturation status. Arterial blood gas, delivery, and ventilation data were analyzed (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 significant).</p></sec><sec><title>Results</title><p id="Par3">Transdermal administration of ANS in NHPs achieved rapid plasma accumulation, with a plasma half-life of 8.9&#x000a0;h, similar to that achieved with IM dosing in clinical practice. In preterm sheep, all 2- and 8-day IM and transdermal ANS patch groups had clinically important and statistically significant improvements in ventilation parameters (umbilical PaCO<sub>2</sub>, pH, tidal volume) compared to saline control.</p></sec><sec><title>Conclusions</title><p id="Par4">We demonstrate, for the first time, the potential for using transdermal ANS for preterm fetal lung maturation. Transdermal ANS administration eliminates the need for injections, pain, and infection risk. Moreover, transdermal ANS delivery demonstrates advantages in dose control, continuity of exposure, and potential to remove drug exposure should the risk of preterm birth resolve. Further development of this technology may improve preterm outcomes through delivery of a low dose, constant fetal steroid exposure.
</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04267-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antenatal corticosteroids</kwd><kwd>Preterm birth</kwd><kwd>Transdermal patch</kwd><kwd>Optimizing route of administration</kwd><kwd>Fetal lung maturation</kwd><kwd>Perinatal medicine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par18">First introduced clinically in 1969, the intramuscular (IM) delivery of antenatal steroids (ANS) has since the mid-1990s become one of the most widely prescribed medications in obstetric practice. ANS therapy is now routinely administered to women at risk of preterm birth (PTB; delivery before 37 weeks&#x02019; completed gestation). ANS primarily promotes accelerated maturation of the preterm fetal lung, resulting in improved perinatal survival and reduced risk of respiratory morbidity [<xref ref-type="bibr" rid="CR1">1</xref>]. PTB is one of the most serious obstetric syndromes. In-country rates of PTB vary from as low as 4% to as high as 14%, resulting in upwards of 15 million preterm births and over 1 million deaths worldwide each year [<xref ref-type="bibr" rid="CR2">2</xref>]. In high-resource settings, ANS coverage (i.e., the percentage of at-risk pregnancies receiving ANS therapy) is very high&#x02014;but likely underrepresents the true number of mothers and fetuses exposed to ANS. This is because a sizable percentage of women treated with ANS go on to deliver at term; indeed, evidence suggests that in some centers up to 50% of ANS-treated patients are incorrectly assessed to be at imminent risk of PTB and go on to deliver after an extended period of time, or at term [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. Additionally, the clinical indications for ANS therapy in many centers are now expanding beyond women at risk of PTB at or before 34 weeks&#x02019; gestation [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], to now include women at risk of delivering between 34 and 37 weeks, or by cesarean section at term in order to reduce the risk of transient tachypnoea of the newborn [<xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, an increasingly large percentage of the pregnancy population may be exposed to ANS therapy, depending on local preterm birth risk, obstetric practice, and ANS treatment guidelines.
</p><p id="Par19">Despite the long-established clinical use of IM ANS, key uncertainties persist. Firstly, the therapeutic window of ANS therapy is poorly defined. The window of efficacy has generally been taken as being relatively short, being between 48 h and 7 days for maximal benefit [<xref ref-type="bibr" rid="CR3">3</xref>]. However, as noted by several investigators, the concept of treatment durability has never been formally studied in a human population and is likely dependent on a range of factors including gestational age, pregnancy conditions justifying their use, and perinatal care standards [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. There is, however, a sizable amount of clinical trial data demonstrating that a large proportion of women treated with ANS deliver at periods significantly longer than 7 days post treatment, with many going on to deliver at term [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par20">Secondly, there is increasing evidence from both animal and clinical studies that ANS exposure is associated with short- and long-term off-target, harmful effects on fetal development and well-being, particularly in preterm-treated fetuses born at term. These concerns include increased risk of fetal growth restriction [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], neurobehavioral/psychiatric disorders [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], hypothalamic&#x02013;pituitary&#x02013;adrenal (HPA) axis dysregulation [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], childhood sepsis/severe infection [<xref ref-type="bibr" rid="CR20">20</xref>], and adult-onset cardiovascular [<xref ref-type="bibr" rid="CR21">21</xref>] and metabolic dysfunction [<xref ref-type="bibr" rid="CR22">22</xref>]. It is true that these findings, particularly in humans, are based on limited long-term follow-up data, often derived from clinical populations with significant loss to follow-up. Additionally, they reflect preterm populations and outcomes that, due to substantial changes in clinical practice over the past half-century, differ markedly from those managed in high-resource settings today. However, the potential impact of these side effects, especially in pregnancies where the benefits would be minimal, warrants close scrutiny.</p><p id="Par21">Furthermore, despite optimal treatment, a sizable percentage of preterm babies fail to respond to ANS therapy with improved respiratory outcomes (ANS non-responsiveness) [<xref ref-type="bibr" rid="CR23">23</xref>], highlighting significant uncertainty regarding the basis of the substantial residual respiratory morbidity observed in ANS-treated human and animal populations. The etiology of poor or failed ANS responsiveness in the setting of accurately administered treatment remains incompletely understood, but ANS regimens and the particular pharmacokinetic profile of such regimens have been proposed as one major potential cause [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par22">All current clinical regimens of ANS utilize IM dosing, which delivers a pulsatile drug exposure to both mother and fetus. Importantly, recent evidence from animal models suggests that the pulsatile pharmacokinetic profile of IM dosing may be suboptimal for lung maturation [<xref ref-type="bibr" rid="CR24">24</xref>] and may additionally increase the risk of harmful neurodevelopment-associated transcriptional changes, compared to a constant ANS fetal exposure [<xref ref-type="bibr" rid="CR25">25</xref>]. Furthermore, an extensive body of animal literature is now available to show that the maximal concentrations achieved using current pulsatile IM clinical doses of ANS are unnecessarily excessive and may in fact degrade lung maturation responses relative to lower magnitude, constant exposures [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. By comparison, a constant, reduced dose exposure of ANS has been shown to be optimal for lung maturation and potentially less harmful to the fetus compared to pulsatile exposures [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par23">Noting that the intravenous administration of steroids is likely of limited practical feasibility (especially in low- and middle-income settings), these observations have led us to explore the delivery of ANS via a transdermal patch. Such an approach may allow us to exploit current understanding of ANS pharmacokinetics and pharmacodynamics to promote optimal (maximal benefit and lowest risk) fetal lung maturation. In selecting this route of drug administration, we sought to develop a means by which to achieve a constant steroid exposure with a maximal concentration significantly lower than that achieved by IM ANS regimens in current clinical use. Transdermal patches belong to the class of transdermal drug delivery systems. They consist of a flexible, multi-layer, single-dose preparation of varying size containing one or more active substances. Patches are applied to the intact skin for systemic absorption of the agent. The present report describing the development of a transdermal betamethasone phosphate patch is comprised of three sub-studies (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Experimental design. <bold>A</bold> Development of betamethasone gel and loading onto transdermal patch. <bold>B</bold> Pharmacokinetic study of transdermal betamethasone patch in female, non-pregnant cynomolgus macaques. <bold>C</bold> Efficacy study of transdermal compared to intramuscular betamethasone antenatal steroid route of administration in a preterm sheep model of pregnancy and ventilation. Created in BioRender. Carter, S. (2025) <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/a26j314">https://BioRender.com/a26j314</ext-link></p></caption><graphic xlink:href="12916_2025_4267_Fig1_HTML" id="MO1"/></fig></p><p id="Par24">In the first sub-study, we generated and tested a transdermal betamethasone phosphate delivery patch using a series of in vitro stability and ex vivo perfusion models. In the second sub-study, we utilized a non-human primate model to investigate the systemic pharmacokinetic profile of betamethasone phosphate delivered using the transdermal betamethasone patch. In the third sub-study, we investigated, using a preterm sheep model of pregnancy, the efficacy of transdermal betamethasone delivery in promoting preterm fetal lung maturation compared against placebo negative control and a clinically utilized IM betamethasone regimen. Herein, we show that transdermal delivery of betamethasone phosphate rapidly achieves therapeutic plasma levels in non-human primates and promotes rapid precocious maturation of the preterm fetal ovine lung.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par25">All animal studies were undertaken according to the NHMRC Australian code for the care and use of animals for scientific purposes, which incorporates the 3R&#x02019;s (refinement, replacement, and reduction).</p><sec id="Sec3"><title>Sub-study 1: Transdermal betamethasone patch</title><p id="Par26">The complete methodology of the preparation for the transdermal betamethasone patch can be found in the Additional Files&#x02014;Methodology. Figure <xref rid="Fig1" ref-type="fig">1</xref>A graphically represents the transdermal patch production process. Each patch used in this report contained 3.5&#x02013;3.9 g of betamethasone-loaded drug reservoir (10% of betamethasone sodium phosphate).</p></sec><sec id="Sec4"><title>Sub-study 2: Pharmacokinetic study of transdermal antenatal glucocorticoid patch in non-pregnant, female cynomolgus macaques</title><p id="Par27">Pharmacokinetic studies were conducted in Non-Human Primates (NHP) to confirm transdermal delivery of a maternal plasma betamethasone dose necessary for fetal lung maturation (i.e., 20 ng/ml or more in the sheep, 7 ng/ml or more in the NHP and human, based on maternofetal transplacental steroid gradients in these species) [<xref ref-type="bibr" rid="CR28">28</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>B). NHPs (cynomolgus macaques) were bred by the National Large Animal Research Facility (NLARF) in Tuas, Singapore and either group housed (3&#x02013;5 NHPs) or housed in single pens (dimensions 2.4 m&#x02009;&#x000d7;&#x02009;2.1 m&#x02009;&#x000d7;&#x02009;2.4 m). Closely adjacent cage mates were constantly present for enrichment. Staff provided additional food treats for stimulation. The health status of NHPs was checked daily by technical staff. A NHP veterinarian also reviewed animal welfare at least twice a week. Adult female, non-pregnant cynomolgus macaques (<italic>n</italic>&#x02009;=&#x02009;2) were sedated with IM injection of ketamine 10&#x02013;12 mg/kg into the hind leg prior to a 2 ml baseline blood collection from the femoral vein. NHPs were shaved down to the skin along the central back (ventral surface) in order to allow secure application of the transdermal betamethasone patch. The patch was further secured and reinforced with strapping tape applied over the top of the patch. A customized jacket was then fitted and secured with cable ties to prevent the animals from disturbing the patch. One hourly blood collections (2 ml volume) were then taken from 0 to 12 h. Because of ethical limitations, for NHP 1, blood samples were collected at baseline (0 h) and then from 1 to 6 h. For NHP 2, blood samples were collected at baseline and then from 7 to 12 h. The patch was then removed at <italic>t</italic>&#x02009;=&#x02009;12 h, and a 14-day washout period was undertaken before the experiment was repeated with 2 ml blood collections occurring from 13 to 24 h (Fig. <xref rid="Fig1" ref-type="fig">1</xref>B). For NHP 1, blood samples were collected at baseline then from 13 to 18 h. For NHP 2, blood samples were collected at baseline then from 19 to 24 h. All blood samples were collected via separate venepuncture and collected in EDTA tubes. No further sedation was required beyond baseline administration. Blood samples were promptly centrifuged (1000 g for 10 min at 20 &#x000b0;C) to separate plasma. Plasma was then frozen at&#x02009;&#x02212;&#x02009;80 &#x000b0;C before being subjected to LC&#x02013;MS analysis. At the conclusion of the study, the NHPs were recovered and returned to the troop located at the NLARF Singapore for ongoing care.</p></sec><sec id="Sec5"><title>QTRAP LC&#x02013;MS/MS assay for quantification of plasma betamethasone and pharmacokinetic analysis</title><p id="Par28">The full methodology for the QTRAP LC&#x02013;MS/MS assay can be found in the Additional Files&#x02014;Methodology. In this study, data from two animals were compiled and averaged to assess plasmatic concentrations, which were subsequently analyzed using PKSolver (add-in excel program for pharmacokinetic analysis <ext-link ext-link-type="uri" xlink:href="https://doi.org/">https://doi.org/</ext-link>10.1016/j.cmpb.2010.01.007). The analysis employed a linear up-log down method with a specified dose of applied transdermal patches per monkey. To estimate the pharmacokinetic parameters, the elimination rate and half-life were calculated by considering all the time points after the maximum concentration time (Tmax) of 17 h. This approach enables a comprehensive understanding of the drug&#x02019;s life in the plasma, facilitating a characterization of its elimination kinetics post-administration.</p></sec><sec id="Sec6"><title>Sub-study 3: Transdermal betamethasone phosphate patch efficacy study in a preterm pregnant sheep model</title><p id="Par29">Date-mated merino ewes carrying a singleton fetus were supplied by a livestock provider (A8 Darkan, Australia), and experiments were carried out during the regular breeding season. All sheep were kept in outdoor group pens until the time of delivery and euthanasia. Ewes received an intramuscular injection of 150 mg medroxyprogesterone acetate (Depo-Provera, Pfizer, New York, NY) on 117&#x02009;&#x000b1;&#x02009;1 day of gestational age (dGA) to decrease the risk of steroid-induced premature labor. Antenatal progesterone has been previously reported not to impact fetal lung maturation in the sheep [<xref ref-type="bibr" rid="CR29">29</xref>]. The left and right lateral abdomen of the pregnant ewe was shaved to allow for patch application, and baseline maternal blood samples (10 ml in EDTA tubes) were collected from the subcutaneous abdominal vein for analysis at 0800 h, 24 h prior to allocation to the treatment group. Animals were then randomly allocated to one of five intervention groups, with the first treatment given at 0800 h to control for circadian effects (Fig. <xref rid="Fig1" ref-type="fig">1</xref>C):</p><p id="Par30">
<list list-type="simple"><list-item><label>i)</label><p id="Par31">Saline Control Group, 2&#x02009;&#x000d7;&#x02009;2 ml intramuscular (IM) injections of sterile normal saline at 24-h intervals&#x02009;+&#x02009;sham patch (<italic>n</italic>&#x02009;=&#x02009;14).</p></list-item><list-item><label>ii)</label><p id="Par32">2D IM ANS Group, 2&#x02009;&#x000d7;&#x02009;0.25 mg/kg maternal IM injections of betamethasone phosphate&#x02009;+&#x02009;betamethasone acetate (Celestone, MSD) at 24-h intervals&#x02009;+&#x02009;sham patch, with delivery 2 days after patch administration (<italic>n</italic>&#x02009;=&#x02009;14).</p></list-item><list-item><label>iii)</label><p id="Par33">8D IM ANS Group, 2&#x02009;&#x000d7;&#x02009;0.25 mg/kg maternal IM injections of betamethasone phosphate&#x02009;+&#x02009;acetate (Celestone) at 24-h intervals&#x02009;+&#x02009;sham patch, with delivery 8 days after first administration (<italic>n</italic>&#x02009;=&#x02009;11).</p></list-item><list-item><label>iv)</label><p id="Par34">2D Transdermal ANS Patch Group, 2&#x02009;&#x000d7;&#x02009;2 ml IM injections of sterile normal saline at 24-h intervals&#x02009;+&#x02009;2&#x02009;&#x000d7;&#x02009;transdermal betamethasone phosphate patches applied, with delivery 2 days after patch placement (<italic>n</italic>&#x02009;=&#x02009;20). The 2-day Transdermal ANS Patch Group models a brief ANS treatment to delivery interval.</p></list-item><list-item><label>v)</label><p id="Par35">8D Transdermal ANS Patch Group, 2&#x02009;&#x000d7;&#x02009;2 ml IM injections of sterile normal saline at 24-h intervals&#x02009;+&#x02009;2&#x02009;&#x000d7;&#x02009;transdermal betamethasone phosphate patches applied for 48 h and then replaced with 2&#x02009;&#x000d7;&#x02009;new betamethasone phosphate patches. These second patches remained in place until delivery 8 days after patch placement (<italic>n</italic>&#x02009;=&#x02009;11). The 8-day Transdermal ANS Patch Group models an extended ANS treatment to delivery interval, consistent with current clinical ANS use. All ANS patches and sham patches were placed on the shaved abdominal sites to facilitate adhesion. Sham patches consisted of adhesive strapping tape similar to that found on the ANS patch without any further additives.</p></list-item></list>
</p><p id="Par36">Five animals in 8D IM ANS group spontaneously delivered preterm prior to protocol completion (a recognized complication of intramuscular betamethasone in sheep) without investigator input, and thus both ewe and lamb were euthanized as per animal ethics approval with IV pentobarbital (160 mg/kg) and removed from analysis. One animal from the saline control group was identified as an outlier based on 30 min PaCO<sub>2</sub> after Dixon&#x02019;s Q test at a 95% confidence level and subsequently removed from further analysis. The first 10 animals in the 2D Patch ANS group were removed from analysis as it was noted 24 h prior to delivery that their transdermal patches had failed to adhere to the skin and were completely or partially dislodged. Confirmation of a lack of drug transfer secondary to poor patch adherence was made via LC&#x02013;MS analysis showing no drug in maternal or fetal circulation at delivery (data not shown). Thereafter, transdermal patches were reinforced with strapping tape to facilitate adherence to the maternal skin and visually inspected daily. Saline control and IM ANS groups also had sham patches applied to blind investigators to treatment. All animals were surgically delivered at 123&#x02009;&#x000b1;&#x02009;1 days&#x02019; gestational age (dGA; Term&#x02009;=&#x02009;150 dGA). The final group sizes and configurations analyzed in this sub-study (Table <xref rid="Tab1" ref-type="table">1</xref>) were thus as follows: Saline Control Group (<italic>n</italic>&#x02009;=&#x02009;13); 2D IM ANS Group (<italic>n</italic>&#x02009;=&#x02009;14); 8D IM ANS Group (<italic>n</italic>&#x02009;=&#x02009;6); 2D ANS Patch Group (<italic>n</italic>&#x02009;=&#x02009;10); 8D ANS Patch Group (<italic>n</italic>&#x02009;=&#x02009;11).</p><p id="Par37">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of intervention group sizes</p></caption><graphic position="anchor" xlink:href="12916_2025_4267_Tab1_HTML" id="MO2"/></table-wrap></p></sec><sec id="Sec7"><title>Delivery and ventilatory assessments</title><p id="Par38">Maternal blood samples were taken immediately prior to operative delivery (10 ml in EDTA tube) from the subcutaneous abdominal vein and then centrifuged (1000 g for 10 min at 20 &#x000b0;C) to separate plasma. An intravenous catheter was placed in the right cephalic vein; ewes then received an intravenous bolus of midazolam (0.5 mg/kg) and ketamine (10 mg/kg) for the induction of deep anesthesia. A 3-ml injection of 2% (20 mg/ml) lidocaine was administered at L6/L7 for spinal analgesia. A hysterotomy was then performed, and the head of the fetus was delivered through abdominal and uterine incisions. A 4.5-mm fetal endotracheal tube was then secured by tracheostomy. The fetus was then delivered, and the ewe euthanized under anesthesia at the conclusion of the surgery as per animal ethics approval with IV pentobarbital (160 mg/kg); confirmation of cessation of life was made with a stethoscope. Fetal venous umbilical cord plasma samples were taken for analysis during delivery and immediately prior to commencing ventilation. The lamb was weighed, dried, and placed in a radiant warmer bed (CosyCot, Fisher &#x00026; Paykel Healthcare, New Zealand) under a plastic insulating wrap (Neowrap, Fisher &#x00026; Paykel, NZ). Mechanical ventilation (Fabian HFO, Accutronic Medical Systems AG, Switzerland) was immediately commenced with the following settings: peak inspiratory pressure (PIP) of 35 cmH<sub>2</sub>O, positive end-expiratory pressure (PEEP) of 5 cmH<sub>2</sub>O, respiratory rate (RR) of 50 breaths per minute, inspiratory time (iT) of 0.5 s, using 100% heated and humidified oxygen. The standard use of 100% oxygen allows the comparison of oxygenation through the partial arterial pressure of oxygen among the groups. Investigators operating the ventilators were blinded to the animal treatment groups.</p><p id="Par39">An umbilical artery was catheterized for blood sampling and administration of supplemental anesthesia with ketamine (5 mg/kg) as necessary. The tidal volume (V<sub>T</sub>) was continuously measured, and the PIP was adjusted to keep the V<sub>T</sub> between 7.0 and 8.0 ml/kg but with PIP limited to 35 cmH<sub>2</sub>O. At 10, 20, and 30 min of ventilation, we measured temperature, blood pressure (measured via umbilical artery catheter [DTX-Plus Disposable transducer, Merit Medical]), ventilator data (PIP, VT, and compliance), and performed the following blood gas measurements: pH, PCO<sub>2</sub> (mmHg), PO<sub>2</sub> (mmHg), O<sub>2</sub> saturation (SO<sub>2</sub>, %), total hemoglobin (Hb, g/dL), lactate (mmol/L), and glucose (Glu, mg/dL) levels (all using a Siemens RapidPoint 500, Munich, Germany). Dynamic compliance (Cdyn, ml/cmH<sub>2</sub>O/kg) was recorded as measured by the ventilator. The ventilation efficiency index (VEI) was calculated using the formula VEI&#x02009;=&#x02009;3800/(RR&#x02009;&#x000d7;&#x02009;(PIP&#x02009;&#x02212;&#x02009;PEEP)&#x02009;&#x000d7;&#x02009;PCO<sub>2</sub> (mm Hg)) [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec8"><title>Lung assessment</title><p id="Par40">After 30 min of ventilation, lambs were euthanized under anesthesia as per animal ethics approval with IV pentobarbital (160 mg/kg) and disconnected from the ventilator. Confirmation of cessation of life was made using a stethoscope. The lambs were weighed, and the chest was opened for visual evaluation of gross lung injury (pulmonary hemorrhage, pulmonary interstitial emphysema, gas pockets within the lung or subpleural dissection), with observations performed by the same investigator. A deflation pressure&#x02013;volume curve was measured after air inflation of the lungs to a pressure of 40 cmH<sub>2</sub>O consistent with the methodology reported by Ikegami et al. and Fee et al. Briefly, fetal lungs were sequentially inflated to a static pressure of 40 cmH<sub>2</sub>O with volumes recorded at 0, 5, 10, 15, 20, 30 and 40 cmH<sub>2</sub>O to generate an inflation curve with assessment for lung damage occurring during inflation (pulmonary blebs, pneumothorax). Pressure was then released over the same increments with volumes recorded to generate a deflation curve [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Volume at a pressure of 40 cmH<sub>2</sub>O was calculated using fetal weight after ventilation (kg) as V<sub>40</sub> (ml/kg).</p></sec><sec id="Sec9"><title>Liquid chromatography-mass spectrometryLC&#x02013;MS in sheep studies</title><p id="Par41">LC&#x02013;MS was performed on all maternal (baseline and delivery) and fetal (delivery) plasma samples to assess betamethasone concentrations respectively, as previously reported [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec10"><title>Statistical analysis (NHP and sheep sub-studies)</title><p id="Par42">Statistical analysis was performed using IBM SPSS Statistics for Windows Version 28.0.1.0. A chi-square test was used to test the differences of nominal values between groups. All continuous data were tested for normality with Shapiro&#x02013;Wilk tests. Delivery and ventilation data were tested for significance with Kruskal&#x02013;Wallis or ANOVA followed by Dunnett&#x02019;s <italic>t</italic> (2-sided) and Tukey HSD when variance was equal, and Dunnett&#x02019;s T3 when variance was unequal as post hoc analysis for multiple comparisons against saline control. Data are presented in tables and as box and whisker plots with mean indicated by X. <italic>P</italic>-values less than 0.05 were taken as significant. Outlier testing was performed utilizing Dixon&#x02019;s Q test at a 95% confidence level.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Development of betamethasone transdermal patch</title><p id="Par43">The betamethasone patch formulation characteristics, stability, and in vitro and ex vivo skin permeation testing results are described in the Additional Files (Additional Results, Additional Table <xref rid="Tab1" ref-type="table">1</xref>, Additional Fig. <xref rid="Fig1" ref-type="fig">1</xref>). In brief, we demonstrate that the different betamethasone formulations, administered via transdermal patch in this study, had comparable delivery rates and retention profiles.</p></sec><sec id="Sec13"><title>Pharmacokinetics of transdermal betamethasone glucocorticoid patch in non-pregnant, female cynomolgus macaques</title><p id="Par44">No betamethasone was detected by LC&#x02013;MS at baseline in any animal prior to application of the patch. We then performed serial hourly blood sampling over 24 h divided between two NHP animals, as described above, in order to confirm that our betamethasone patches achieved a sufficiently high concentration of plasma betamethasone to elicit fetal lung maturation (Fig. <xref rid="Fig1" ref-type="fig">1</xref>B). Plasma samples underwent LC&#x02013;MS analysis for betamethasone plasma concentration levels, revealing a constant pharmacokinetic exposure profile (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The half-life of betamethasone in plasma was 8.9 h. There was rapid accumulation of betamethasone in the plasma, with a concentration&#x02009;&#x0003e;&#x02009;50 ng/ml achieved within 1 h of patch administration.</p><p id="Par45">
<fig id="Fig2"><label>Fig. 2</label><caption><p>The pharmacokinetic plasma profile of a betamethasone antenatal steroid patch in non-pregnant, cynomolgus macaques over a 24-h period demonstrates a constant exposure. Betamethasone plasma concentrations in ng/ml. For animal welfare reasons, patches were removed after the initial 12-h sampling period followed by a 14 day washout period prior to re-application of the patches and subsequent 13&#x02013;24 h sampling. Image edited in BioRender</p></caption><graphic xlink:href="12916_2025_4267_Fig2_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec14"><title>Transdermal betamethasone patch efficacy study in preterm sheep model of pregnancy <italic>group delivery data</italic></title><p id="Par46">Delivery data for each group are summarized in Table <xref rid="Tab2" ref-type="table">2</xref>. There was no significant difference in birthweight, weight after ventilation, sex, umbilical PaCO<sub>2</sub>, pH, or lactate between any of the groups. Mean lung weight per birthweight was significantly different between groups; however, post hoc analysis showed no significant difference between saline control and any steroid-treated groups. 2-day intramuscular steroid group animals did, however, demonstrate significantly smaller mean lung weight per birthweight measurements when compared to 2-day transdermal patch (<italic>p</italic>&#x02009;=&#x02009;0.037 [Dunnett T3]) as well as 8-day transdermal patch group animals (<italic>p</italic>&#x02009;=&#x02009;0.033 [Dunnett T3]).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Delivery data. Cord measurements were taken from the umbilical artery</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><bold>Saline control</bold></th><th align="left"><bold>2D ANS</bold></th><th align="left"><bold>2D Patch</bold></th><th align="left"><bold>8D ANS</bold></th><th align="left"><bold>8D Patch</bold></th><th align="left"><bold>Test</bold></th><th align="left"><bold><italic>p</italic></bold><bold> value</bold></th></tr></thead><tbody><tr><td align="left">Group size</td><td align="left">13</td><td align="left">14</td><td align="left">10</td><td align="left">6</td><td align="left">11</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Median gestational age (d) (range)</td><td align="left"><p>123</p><p>(122&#x02013;124)</p></td><td align="left"><p>124</p><p>(122&#x02013;124</p></td><td align="left"><p>124</p><p>(124&#x02013;124)</p></td><td align="left"><p>122</p><p>(122&#x02013;122)</p></td><td align="left"><p>122</p><p>(122&#x02013;124)</p></td><td align="left">Kruskal&#x02014;Wallis</td><td align="left">0.07</td></tr><tr><td align="left">Mean birthweight (kg) (Std)</td><td align="left">2.89&#x02009;&#x000b1;&#x02009;0.32</td><td align="left">2.79&#x02009;&#x000b1;&#x02009;0.49</td><td align="left">2.92&#x02009;&#x000b1;&#x02009;0.17</td><td align="left">2.49&#x02009;&#x000b1;&#x02009;0.16</td><td align="left">2.93&#x02009;&#x000b1;&#x02009;0.33</td><td align="left">1 way ANOVA</td><td align="left">0.3</td></tr><tr><td align="left">Sex (M/F)</td><td align="left">6/7</td><td align="left">7/7</td><td align="left">3/7</td><td align="left">6/0</td><td align="left">6/5</td><td align="left">Chi-square</td><td align="left">0.1</td></tr><tr><td align="left">Mean cord pH (Std)</td><td align="left">7.32&#x02009;&#x000b1;&#x02009;0.05</td><td align="left">7.36&#x02009;&#x000b1;&#x02009;0.03</td><td align="left">7.36&#x02009;&#x000b1;&#x02009;0.04</td><td align="left">7.34&#x02009;&#x000b1;&#x02009;0.04</td><td align="left">7.35&#x02009;&#x000b1;&#x02009;0.03</td><td align="left">1 way ANOVA</td><td align="left">0.08</td></tr><tr><td align="left">Mean cord PC02 (mmHg) (Std)</td><td align="left">52.0&#x02009;&#x000b1;&#x02009;7.7</td><td align="left">49.0&#x02009;&#x000b1;&#x02009;3.4</td><td align="left">49.9&#x02009;&#x000b1;&#x02009;5.6</td><td align="left">54.0&#x02009;&#x000b1;&#x02009;2.0</td><td align="left">49.2&#x02009;&#x000b1;&#x02009;3.9</td><td align="left">1 way ANOVA</td><td align="left">0.21</td></tr><tr><td align="left">Mean cord lactate (mmol/L) (Std)</td><td align="left">2.41&#x02009;&#x000b1;&#x02009;0.7</td><td align="left">2.58&#x02009;&#x000b1;&#x02009;0.8</td><td align="left">2.50&#x02009;&#x000b1;&#x02009;1.0</td><td align="left">1.6&#x02009;&#x000b1;&#x02009;0.4</td><td align="left">2.1&#x02009;&#x000b1;&#x02009;0.4</td><td align="left">1 way ANOVA</td><td align="left">0.06</td></tr><tr><td align="left">Mean lung weight per birthweight (g/kg) (Std)</td><td align="left">37.9&#x02009;&#x000b1;&#x02009;5.4</td><td align="left">33.6&#x02009;&#x000b1;&#x02009;5.2</td><td align="left">39.2&#x02009;&#x000b1;&#x02009;2.8</td><td align="left">39.9&#x02009;&#x000b1;&#x02009;3.1</td><td align="left">39.1&#x02009;&#x000b1;&#x02009;2.8</td><td align="left">1 way ANOVA</td><td align="left">0.01</td></tr><tr><td align="left">Mean birthweight post ventilation (kg) (Std)</td><td align="left">2.70&#x02009;&#x000b1;&#x02009;0.30</td><td align="left">2.58&#x02009;&#x000b1;&#x02009;0.45</td><td align="left">2.70&#x02009;&#x000b1;&#x02009;0.17</td><td align="left">2.32&#x02009;&#x000b1;&#x02009;0.17</td><td align="left">2.72&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">1 way ANOVA</td><td align="left">0.2</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec15"><title>Transdermal and intramuscular administration of betamethasone achieves clinically important improvements in preterm lung function relative to control</title><p id="Par47">Umbilical arterial PaCO<sub>2</sub> levels serve as a well-established and validated measure of functional fetal lung maturation status, with lower values representing a more mature lung and effective gas exchange [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. PaCO<sub>2</sub> measurements taken at 10, 20, and 30 min of ventilation are shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>A. Compared to Control, all Patch and IM ANS groups had significant improvements in PaCO<sub>2</sub> consistent with accelerated preterm lung maturation (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A). Noting that the study was powered to assess treatment differences vs. saline control (and not to determine differences between steroid treatments&#x02014;which would require vastly larger group sizes that are impractical in a pregnant sheep study), there was no statistical difference in PaCO<sub>2</sub> at any time point of ventilation between 2-day or 8-day injection or patch treatment animals. These data demonstrate, for the first time, effective preterm lung maturation from transdermal patch administration of betamethasone phosphate in a large animal model of pregnancy.</p><p id="Par48">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Neonatal ventilation outcomes for each intervention group, Saline (<italic>n</italic> = 13), ANS 2&#x02009;d (<italic>n</italic> = 14), Patch 2&#x02009;d (<italic>n</italic> = 10), ANS 8&#x02009;d (<italic>n</italic> = 6), and Patch 8&#x02009;d (<italic>n</italic> = 11) groups. <bold>A</bold> Umbilical PaCO<sub>2</sub> (mmHg) at 10, 20 and 30 minutes of ventilation. <bold>B </bold>Umbilical pH at 10, 20 and 30 minutes of ventilation.
<bold>C </bold>Ventilation Efficiency Index (VEI) at 10, 20 and 30 minutes of ventilation. <bold>D</bold> Tidal Volume per birth weight (ml/kg) at 10, 20, and 30 minutes of ventilation. The asterisk indicates a significant difference among the groups. X indicates the mean</p></caption><graphic xlink:href="12916_2025_4267_Fig3_HTML" id="MO4"/></fig>
</p><p id="Par49">Additional validated measures of preterm functional lung maturation (umbilical artery pH, Ventilation Efficiency Index [VEI] and neonatal lung tidal volume adjusted for birthweight) are illustrated in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. Compared to saline control, all steroid treatment groups had significantly improved umbilical arterial pH at all ventilation time points (Fig. <xref rid="Fig3" ref-type="fig">3</xref>B). There were no significant differences at any time point between 2-day or 8-day injection or patch treatment animals.</p><p id="Par50">Compared to saline control, VEI was significantly improved at all ventilation time points in the 2-day intramuscular steroid group animals, whilst 8-day transdermal patch group animals had significant improvement at 20 min of ventilation (Fig. <xref rid="Fig3" ref-type="fig">3</xref>C). Neonatal lung tidal volume adjusted for birthweight was significantly improved at all ventilation time points in all ANS groups compared to saline control (Fig. <xref rid="Fig3" ref-type="fig">3</xref>D). There was no significant difference at any time point between 2-day or 8-day injection or patch treatment animals. Additional measures of functional lung maturation, lung compliance, and umbilical PaO<sub>2</sub> are discussed and presented in the Additional Results and Additional Fig. <xref rid="Fig2" ref-type="fig">2</xref>.</p><p id="Par51">The neonatal cardiovascular effects of transdermal and IM delivery of betamethasone are discussed in the Additional Results and Additional Fig. <xref rid="Fig3" ref-type="fig">3</xref>.</p></sec><sec id="Sec16"><title>Use of a transdermal betamethasone patch achieves robust static compliance at necropsy</title><p id="Par52">The neonatal lung pressure&#x02013;volume relationship was explored post-ventilation and euthanasia in each animal according to group. Body weight-standardized hysteresis loops were constructed for each treatment group as described above. Data are presented in Fig. <xref rid="Fig4" ref-type="fig">4</xref>. Compared to saline control, both 2-day intramuscular and 8-day transdermal patch animals had significantly larger lung volumes at inflation and deflation pressures of 30 and 40 cmH<sub>2</sub>O, respectively. Only the 8-day transdermal patch group animals had significantly larger volumes during deflation from 20 to 5 cmH<sub>2</sub>O, relative to saline control. These findings are consistent with clinically important early maturation of the preterm lung. Post ventilation, visual assessment of the lung for gross lung damage was conducted and revealed lung blebs in 2 animals from the 2-day IM ANS group (one also had a pneumothorax), whilst 1 animal in the 2-day transdermal patch group demonstrated lung blebs.</p><p id="Par53">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Pressure-volume relationship for air inflation and deflation of the lung at necropsy for each treatment group. The inferior line from 0 cmH<sub>2</sub>O to 40 cmH<sub>2</sub>O of pressure in each loop is the inflation arm, whilst the superior line from 40 cmH<sub>2</sub>O to 0 cmH<sub>2</sub>O of pressure is the deflation arm. Values represent mean values for each group. Compared to Saline Control, ANS 2&#x02009;d and Patch 8&#x02009;d had significantly larger lung volumes at inflation and deflation pressures of 30 and 40 cmH<sub>2</sub>O. Patch 8&#x02009;d had significantly larger lung volumes during deflation from 20 to 5 cmH<sub>2</sub>O</p></caption><graphic xlink:href="12916_2025_4267_Fig4_HTML" id="MO5"/></fig>
</p></sec><sec id="Sec17"><title>Drug levels achieved by transdermal betamethasone patch in maternal and fetal circulation at delivery</title><p id="Par54">LC&#x02013;MS was performed on all maternal and fetal sheep plasma samples taken at baseline and immediately prior to delivery in order to compare the pharmacokinetic profile of the transdermal patch compared to IM administration. Betamethasone was not detected (limit of detection 1 ng/ml, Signal/Noise ratio&#x02009;&#x0003e;&#x02009;10) in maternal plasma samples at baseline or at any time point for the Saline Control Group Animals. The median maternal plasma betamethasone concentrations for each group are represented in Table <xref rid="Tab3" ref-type="table">3</xref>. Of interest, the 2-day Transdermal Patch Group animals had significantly lower maternal (<italic>p</italic>&#x02009;=&#x02009;0.002 [Tukey HSD]) and fetal (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 [Tukey HSD]) betamethasone plasma concentrations compared to the 2-day Intramuscular ANS group but had broadly equivalent improvements in lung maturation.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>LC&#x02013;MS analysis of betamethasone concentration in maternal and fetal plasma at delivery for each group The symbol &#x0201c;<sup>&#x02660;</sup>&#x0201d; denotes that the limit of detection is 1 ng/ml, Signal/Noise ratio&#x02009;&#x0003e;&#x02009;10; therefore, these results may not be discernible from noise. The asterisk &#x0201c;*&#x0201d; denotes significant difference between 2&#x02009;d Patch and 2D ANS groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><bold>Saline control</bold></th><th align="left"><bold>2D ANS</bold></th><th align="left"><bold>2D Patch</bold></th><th align="left"><bold>8D ANS</bold></th><th align="left"><bold>8D Patch</bold></th></tr></thead><tbody><tr><td align="left">Median Maternal Plasma Betamethasone Concentration ng/ml (Max&#x02013;Min)</td><td align="left"><p>0</p><p>(0&#x02013;0)</p></td><td align="left"><p>5.2</p><p>(0.7&#x02013;8.2)</p></td><td align="left"><p>0.5*</p><p>(0&#x02013;7.8)</p></td><td align="left"><p>0</p><p>(0&#x02013;0)</p></td><td align="left"><p>0.65</p><p>(0&#x02013;3.4)</p></td></tr><tr><td align="left"><p>Median Fetal Plasma Betamethasone Concentration</p><p>ng/ml (Max&#x02013;Min)</p></td><td align="left"><p>0</p><p>(0&#x02013;0)</p></td><td align="left"><p>0.55<sup>&#x02660;</sup></p><p>(0&#x02013;0.9)</p></td><td align="left"><p>0<sup>&#x02660;</sup>,*</p><p>(0&#x02013;0.4)</p></td><td align="left"><p>0.1<sup>&#x02660;</sup></p><p>(0&#x02013;0.2)</p></td><td align="left"><p>0.15<sup>&#x02660;</sup></p><p>(0&#x02013;0.2)</p></td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par55">In this proof of principle study, we have utilized in- vitro, ex-vivo, and in<italic>-</italic>vivo (NHP and pregnant sheep) model systems to demonstrate the potential for the transdermal delivery of betamethasone for functional maturation of the preterm lung in anticipated preterm delivery. Our data show that transdermal betamethasone administration allows for rapid plasma distribution (in the non-human primate) and achieves robust maturation of the preterm ovine lung, with similar improvements (relative to saline control) seen for both intramuscular and transdermal steroid treated animals. Specifically, in our preterm sheep model of pregnancy we have demonstrated similar improvements in functional lung maturation, as measured by umbilical PaCO<sub>2</sub>, pH, and lung tidal volumes adjusted for birthweight at all time points during a 30-min postnatal ventilation (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Importantly, in the 2-day transdermal patch intervention group, broadly equivalent lung maturation was achieved in parallel with greatly reduced (up to 10 times less) maternal and fetal plasma betamethasone concentrations compared with the IM dosing regimen (Table <xref rid="Tab3" ref-type="table">3</xref>).</p><sec id="Sec19"><title>Research implications</title><p id="Par56">The data presented in this study necessitate the undertaking of a sizable body of follow-up research, focusing on fundamental glucocorticoid signalling, optimisation of transdermal patch technology (i.e., better adhesion, assessments of comfort, skin irritation) and the pharmacokinetic and pharmacodynamic effects of transdermal steroid delivery in animal models and human trials.</p><p id="Par57">There is presently no consensus as to whether betamethasone or dexamethasone is the better agent for inducing maturation of the preterm lung. One of the challenges inherent to answering this question (which due to differences in cost, availability, as well as glucocorticoid receptor affinity, is of some importance) is the material differences in their pharmacokinetic profiles [<xref ref-type="bibr" rid="CR36">36</xref>]. The development of antenatal steroid transdermal patch technology now allows for the standardization of delivery of these drugs (i.e., equivalent concentration and duration of exposure at a therapeutic threshold). This will therefore permit, for the first time, a direct comparison of betamethasone and dexamethasone in terms of relative efficacy in driving lung maturation and to investigate their adverse effect profiles (i.e., HPA axis suppression, fetal growth impacts). Moreover, there is increasing evidence that a pulsatile or interrupted maternofetal steroid exposure is associated with degradation of ANS therapy benefit [<xref ref-type="bibr" rid="CR24">24</xref>]. The use of transdermal patch technology will similarly allow us to address this important question, and at the same time assess the relationship between duration of constant steroid exposure to the mother and fetus and the durability of ANS treatment efficacy.</p><p id="Par58">In terms of patch technology development, the loss of several animals early in this study due to poor or failed patch adhesion highlights the importance of optimizing patch physical and adhesive characteristics. It is tempting to speculate that, given the importance of good skin contact, an indicator system warning of patch dehiscence may need to be incorporated into the final patch design, alerting the patient and clinical team to failed adhesion. A further element for refinement in this area will be the amount of drug loaded into the patch and the rate at which it was released. In this initial report, the patch we developed achieved a suprapharmacologic level of maternal plasma betamethasone in the cynomolgus macaque. Given data showing that a constant fetal plasma betamethasone concentration of around 2 ng/ml elicits robust preterm lung maturation, our results show that it will be important to develop a patch delivering a materially lower maternal Cmax, maintained over a longer duration.</p><p id="Par59">These data also foreshadow the need for extensive pharmacokinetic, safety and efficacy testing in pregnant sheep and NHP models, undertaken in tandem with phase I pharmacokinetic trials of GMP-grade transdermal patches in non-pregnant human females. Human clinical trials of a transdermal ANS patch should only be considered once these data are available.</p><p id="Par60">In terms of the wider research context, these data provide further evidence for the argument that low-dose, constant maternofetal steroid exposures are key to robust, lasting maturation of the preterm fetal lung. These data demonstrate that it is not necessary to deliver betamethasone via a traditional IM injection route. Recent evidence from the sheep model of pregnancy showed that a constant fetal exposure of 2 ng/ml of betamethasone is adequate to mature the fetal lung, which equates to just 1% of the current pulsatile betamethasone IM ANS dosing used in many parts of the world [<xref ref-type="bibr" rid="CR27">27</xref>]. Similar findings have been reported from pregnant NHP studies [<xref ref-type="bibr" rid="CR37">37</xref>]. Further studies in sheep by Kemp et al. have also shown that a peak fetal betamethasone exposure above 4 ng/ml produced by pulsatile IM dosing does not benefit the promotion of fetal lung maturation [<xref ref-type="bibr" rid="CR38">38</xref>]. Furthermore, we have previously demonstrated that the pulsatile peaks exhibited by IM dosing of ANS may be associated with less treatment efficacy and possible increased neurodevelopmental harm in comparison to a constant, low dose exposure of betamethasone [<xref ref-type="bibr" rid="CR25">25</xref>]. Overall, these findings suggest that it may be possible to significantly reduce the dosage and therefore fetal exposure to betamethasone through delivery via a transdermal patch.</p></sec><sec id="Sec20"><title>Clinical implications</title><p id="Par61">Other potential delivery routes for ANS such as oral dosing have been studied previously. A study by Jobe et al. compared the pharmacokinetics of oral versus IM dosing of betamethasone and dexamethasone in non-pregnant women and demonstrated similar bioavailability between routes of administration. Furthermore, studies of oral ANS dosing in pregnant sheep and non-human primates also demonstrate a pulsatile pharmacokinetic exposure resulting in functional maturation of the fetal lung [<xref ref-type="bibr" rid="CR39">39</xref>]. These findings suggest that oral ANS dosing in pregnant women would result in a similar pulsatile maternal exposure to IM dosing and would therefore not be as optimal for fetal outcomes as a constant ANS exposure generated by a transdermal patch [<xref ref-type="bibr" rid="CR36">36</xref>]. Additionally, the effects of oral ANS on maternal gastrointestinal tract health are not well understood and may result in further adverse effects.</p><p id="Par62">Secondly, the delivery of ANS via a transdermal patch may allow for immediate removal of additional drug exposure if a patient no longer requires treatment, in stark contrast to an IM dosing approach. This is a significant potential advancement given that a high percentage of women exposed to ANS following a risk assessment for PTB actually go on to deliver at term [<xref ref-type="bibr" rid="CR40">40</xref>]. At present, IM dosing produces a depot effect where, after maternal administration, the mother acts as a drug reservoir for transplacental passage to the fetus [<xref ref-type="bibr" rid="CR27">27</xref>]. Given this pharmacokinetic profile, once IM ANS are administered, it is not possible to remove the drug exposure. This is significant as pharmacokinetic data (albeit in non-pregnant women) demonstrates that the half-life of IM Celestone (combined betamethasone phosphate&#x02009;+&#x02009;acetate) is&#x02009;&#x0003e;&#x02009;59 h, with many women demonstrating detectable betamethasone in circulation up to 14 days after administration [<xref ref-type="bibr" rid="CR36">36</xref>]. Conversely, with transdermal delivery of ANS, if a patient remained undelivered after initial administration or if the clinical picture changed within a day or two of initial PTB risk assessment, then the ANS exposure could be immediately removed by simply removing the patch. This has the potential, therefore, to reduce harmful off-target effects to those women and babies who are incorrectly assessed to be at risk of preterm delivery but go on to deliver late preterm or at term, where the benefits of ANS treatment are significantly reduced but the potential harms remain.</p><p id="Par63">Additional benefit from transdermal over IM delivery of ANS may be in the form of improved patient compliance to treatment. Evidence suggests that low medication adherence may be a significant barrier to health service engagement and treatment, possibly due to the pain associated with IM administration [<xref ref-type="bibr" rid="CR41">41</xref>]. The ASTEROID trial reported that the most common maternal side effect of both dexamethasone and betamethasone IM administration was discomfort at the injection site [<xref ref-type="bibr" rid="CR40">40</xref>]. Avoidance of treatment with IM dosing is of particular importance for needle-phobic patients (up to 1 in 5 people) with those affected more likely to avoid medical treatment involving needles (i.e., current IM ANS dosing regimens) [<xref ref-type="bibr" rid="CR41">41</xref>]. Furthermore, IM dosing of ANS is associated with other increased local site risks, including allergic reaction and infection. In low-resource settings (wherein the preponderance of PTB occurs) elimination of needles may improve the safety of this intervention by eliminating the risk of needle reuse and disease transmission. Reported strategies to help improve patient adherence to treatment include simplification of dosing regimen and mitigation of route of administration adverse effects like pain [<xref ref-type="bibr" rid="CR41">41</xref>]. Therefore, alternative ANS delivery systems, such as a transdermal patch, may improve patient adherence and reduce the need for extended hospital admission, given that the patient could self-administer any repeat dosing with a transdermal patch.</p><p id="Par64">Further, the transdermal patch developed in this study was demonstrated to be heat stable, not requiring refrigeration (Additional results). This supports the potential extended use of the delivery method of glucocorticoids to regional and remote areas where cold chain supply of medications may be limited. Again, this benefit has particular relevance to low-resource environments that continue to have the highest rates of preterm birth.</p><p id="Par65">Finally, the successful systemic delivery of glucocorticoids via a transdermal patch illustrated in this study may have more widely applied clinical indications beyond preterm birth. At present, many other obstetric (congenital adrenal hyperplasia, recurrent miscarriage) [<xref ref-type="bibr" rid="CR42">42</xref>] and non-obstetric conditions require regular glucocorticoid administration (either oral or IM) including autoimmune conditions (systemic lupus erythema, rheumatoid arthritis) [<xref ref-type="bibr" rid="CR43">43</xref>], idiopathic thrombocytopenia [<xref ref-type="bibr" rid="CR44">44</xref>] and myasthenia gravis [<xref ref-type="bibr" rid="CR45">45</xref>]. Therefore, the findings of this study demonstrating successful systemic administration of glucocorticoids by a new route of administration may benefit many obstetric and non-obstetric patients.</p></sec></sec><sec id="Sec21"><title>Limitations</title><p id="Par66">Data presented herein derive from laboratory, NHP, and pregnant sheep models. Accordingly, further work is naturally required before the clinical utility of transdermal ANS delivery can be assessed. The NHP pharmacokinetic study was very small (each time point representing <italic>n</italic>&#x02009;=&#x02009;1) and was based on the staggered use of two animals. These data thus require cautious interpretation. However, given the close agreement of the NHP betamethasone T<sub>1/2</sub> data generated in this study with that of Jobe and colleagues in a large study of non-pregnant humans dosed orally and via intramuscular injection [<xref ref-type="bibr" rid="CR36">36</xref>], the data appear fairly robust.</p><p id="Par67">This study was powered to assess differences in steroid treatment groups to a single saline control group (and not within steroid group differences) in order to minimize animal numbers from an ethical viewpoint. Therefore, although we have reported significant findings within steroid groups, these findings require further assessment in a larger scale study. Furthermore, as indicated by the elimination of 10 animals from the 2-day patch group, the integrity of patch adhesives and maintaining robust patch contact with the skin is key to the efficacy of this delivery approach. Accordingly, future work will need to incorporate both improved physical patch properties and likely a marker for failed skin contact. Future validation work with this delivery system will need to include a larger scale maternofetal pharmacokinetic investigation in pregnant animal models with extended durations of exposure before pilot studies in non-pregnant and pregnant human cohorts.</p><p id="Par68">The impact of fetal sex on lung maturation (both normal maturation processes and in response to exogenous glucocorticoid exposure) is a complex and incompletely understood area of ongoing research. This is an important consideration given that this study reports differences in sex between groups. The established view is that fetal lung maturation in the human is more advanced in the female relative to the male fetus [<xref ref-type="bibr" rid="CR46">46</xref>]. Interestingly, the acute functional lung performance of gestational age and exposure matched sheep fetuses does not differ as a function of fetal sex [<xref ref-type="bibr" rid="CR32">32</xref>]. Ishak and colleagues, taking a structural approach, reported few differences in lung architecture between male and female sheep fetuses at 0.9 term [<xref ref-type="bibr" rid="CR47">47</xref>]. In terms of responses to glucocorticoid therapy, the clinical picture is complex and likely impacted by the multifactorial aetiology of preterm birth itself. Classic studies by Ballard and colleagues [<xref ref-type="bibr" rid="CR48">48</xref>] concluded that antenatal steroid therapy may be less effective in males than in females. In contrast, a recent report detailing the complete data set from the Auckland Steroid Trial noted that the steroid-associated reduction in RDS incidence was greater in males than in females [<xref ref-type="bibr" rid="CR49">49</xref>]. The source(s) of this conflicting picture are unclear but may relate to birth weight and (presumably) the gestational ages of the populations assessed. In the Ballard study the birth weight range assessed was 1.25&#x02013;1.75 kg, whereas in the Auckland Trial report, the mean birth weight in steroid and placebo groups was approximately 2.2 kg. Well-powered large animal studies, with the ability to control for a range of pregnancy variables (gestational age, antenatal exposures, mode of delivery) offer the potential to unpack a number of these potential confounding variables and shed further light on this important element of fetal development.</p><p id="Par69">We did not assess off-target harmful effects (i.e., neurodevelopment) between IM and transdermal dosing of ANS in this proof of principle study. This is a question that is of high clinical importance and is currently being investigated by our group. Of further interest is whether betamethasone compared to dexamethasone exhibits different shelf stabilities, PK, and efficacy profiles when delivered via a transdermal patch.</p></sec><sec id="Sec22"><title>Conclusions</title><p id="Par70">The findings of this study represent a novel and potentially highly translatable optimization of antenatal steroid administration. We demonstrate, for the first time, that both transdermal betamethasone delivery and intramuscular betamethasone delivery achieve robust preterm functional lung maturation in a large animal model of pregnancy. With further development, the transdermal delivery of antenatal steroids has the potential to improve maternal and fetal outcomes for those at risk of preterm birth by exploiting the current pharmacokinetic understanding that a constant, low dose exposure of antenatal steroids is most beneficial for inducing lung maturation and has potentially less damaging off-target side effects compared to current pulsatile IM dosing regimens.</p></sec><sec id="Sec23" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4267_MOESM1_ESM.tif"><caption><p>Additional file 1.&#x000a0;Additional Methodology -&#x000a0;Sub-study 1: preparation of transdermal patches of betamethasone sodium phosphate. -&#x000a0;Sub-study 2: pharmacokinetic study of transdermal antenatal glucocorticoid patch in non-pregnant, female cynomolgus macaques</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12916_2025_4267_MOESM2_ESM.docx"><caption><p>Additional file 2.&#x000a0;Additional Results -&#x000a0;Sub-Study 1: Preparation of transdermal patches of betamethasone sodium phosphate. -&#x000a0;Sub-Study&#x000a0; 3: Additional measures of preterm lung maturation after transdermal and intramuscular administration of betamethasone</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12916_2025_4267_MOESM3_ESM.docx"><caption><p>Additional file 3.&#x000a0;Additional Table 1. Results for pH, tensile strength, contact angle and viscosity for gel formulations with and without betamethasone sodium phosphate powder</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12916_2025_4267_MOESM4_ESM.docx"><caption><p>Additional file 4.&#x000a0;Additional Figures. -&#x000a0;Additional Figure 1. Betamethasone patch sweep analysis, stability and skin permeation testing results. -&#x000a0;Additional Figure 2. Neonatal respiratory outcomes after IM and transdermal ANS administration. -&#x000a0;Additional Figure 3. Neonatal cardiovascular outcomes after IM and transdermal ANS administration</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ANS</term><def><p id="Par6">Antenatal corticosteroids</p></def></def-item><def-item><term>dGA</term><def><p id="Par7">Days gestation age</p></def></def-item><def-item><term>h</term><def><p id="Par8">Hours</p></def></def-item><def-item><term>HPA</term><def><p id="Par11">Hypothalamic pituitary adrenal</p></def></def-item><def-item><term>IM</term><def><p id="Par12">Intramuscular</p></def></def-item><def-item><term>LC-MS</term><def><p id="Par9">Liquid chromatography-mass spectrometry</p></def></def-item><def-item><term>NHP</term><def><p id="Par10">Non-human primates</p></def></def-item><def-item><term>PEEP</term><def><p id="Par15">Positive end expiratory pressure</p></def></def-item><def-item><term>PIP</term><def><p id="Par13">Peak inspiratory pressure</p></def></def-item><def-item><term>PTB</term><def><p id="Par5">Preterm birth</p></def></def-item><def-item><term>RR</term><def><p id="Par16">Respiratory rate</p></def></def-item><def-item><term>V<sub>T</sub></term><def><p id="Par14">Tidal volume</p></def></def-item><def-item><term>VEI</term><def><p id="Par17">Ventilation Efficiency Index</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements
</title><p>The analysis of tensile strength was performed at Department of Mechanical Engineering, Application for the use of Lab. Equipment and Facilities, In Experimental Mechanics/Impact Mechanics Laboratory. Ayca Altay Benetti is supported by National University of Singapore, A-8002435-00-00, which has been created for GAP2002023-03-23.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions
</title><p>Study design and conceptualisation: SC and MK Animal studies: SC, MK,EJ,KS,HU,HW,YK,QW,XL,RO,MB,ZA,BA,TT,NM, YS,HI, MS,SI Laboratory studies: SC,AB,RS Data analysis: SC,AB,RS,GP Manuscript preparation: SC Manuscript review: SC, MK, SI, MC All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by a grant from the Ministry of Education, Government of Singapore (NUHSRO/2021/109/T1/Seed-Sep/02), and by the Women and Infants Research Foundation, Perth, Western Australia, Australia.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par71">For all animals utilized in sub-study 2, the SingHealth Institutional Animal Care and Use Committee (IACUC) reviewed and approved these non-human primate studies prior to work commencing (2024/SHS/1873). For all animals utilized in sub-study 3, the animal ethics committee of The University of Western Australia reviewed and approved these studies prior to work commencing (2023/ET000864).</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par72">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests
</title><p id="Par73">SC and MK are listed as inventors (technologies pertaining to transdermal delivery of steroids for fetal maturation and lung development) on disclosure 2025&#x02013;041.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>McGoldrick</surname><given-names>E</given-names></name><name><surname>Stewart</surname><given-names>F</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name><name><surname>Dalziel</surname><given-names>SR</given-names></name></person-group><article-title>Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth</article-title><source>Cochrane Database Syst Rev</source><year>2020</year><volume>12</volume><fpage>CD004454</fpage><pub-id pub-id-type="pmid">33368142</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2020;12:CD004454.<pub-id pub-id-type="pmid">33368142</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Blencowe</surname><given-names>H</given-names></name><name><surname>Cousens</surname><given-names>S</given-names></name><name><surname>Chou</surname><given-names>D</given-names></name><name><surname>Oestergaard</surname><given-names>M</given-names></name><name><surname>Say</surname><given-names>L</given-names></name><name><surname>Moller</surname><given-names>AB</given-names></name><name><surname>Kinney</surname><given-names>M</given-names></name><name><surname>Lawn</surname><given-names>J</given-names></name></person-group><article-title>Born too soon: the global epidemiology of 15 million preterm births</article-title><source>Reprod Health.</source><year>2013</year><volume>10 Suppl 1</volume><issue>Suppl 1</issue><fpage>S2</fpage><pub-id pub-id-type="pmid">24625129</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, Kinney M, Lawn J. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health. 2013;10 Suppl 1(Suppl 1):S2.<pub-id pub-id-type="pmid">24625129</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Makhija</surname><given-names>NK</given-names></name><name><surname>Tronnes</surname><given-names>AA</given-names></name><name><surname>Dunlap</surname><given-names>BS</given-names></name><name><surname>Schulkin</surname><given-names>J</given-names></name><name><surname>Lannon</surname><given-names>SM</given-names></name></person-group><article-title>Antenatal corticosteroid timing: accuracy after the introduction of a rescue course protocol</article-title><source>Am J Obstet Gynecol</source><year>2016</year><volume>214</volume><issue>1</issue><fpage>120. e121</fpage><lpage>120. e126</lpage></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Makhija NK, Tronnes AA, Dunlap BS, Schulkin J, Lannon SM. Antenatal corticosteroid timing: accuracy after the introduction of a rescue course protocol. Am J Obstet Gynecol. 2016;214(1):120. e121-120. e126.</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Souter</surname><given-names>V</given-names></name><name><surname>Kauffman</surname><given-names>E</given-names></name><name><surname>Marshall</surname><given-names>AJ</given-names></name><name><surname>Katon</surname><given-names>JG</given-names></name></person-group><article-title>Assessing the potential impact of extending antenatal steroids to the late preterm period</article-title><source>Am J Obstet Gynecol</source><year>2017</year><volume>217</volume><issue>4</issue><fpage>461.e461</fpage><lpage>461.e467</lpage></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Souter V, Kauffman E, Marshall AJ, Katon JG. Assessing the potential impact of extending antenatal steroids to the late preterm period. Am J Obstet Gynecol. 2017;217(4):461.e461-461.e467.</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ali Khan</surname><given-names>A</given-names></name><name><surname>Cartwright</surname><given-names>R</given-names></name><name><surname>Gissler</surname><given-names>M</given-names></name><name><surname>J&#x000e4;rvelin</surname><given-names>M-R</given-names></name></person-group><article-title>Antenatal corticosteroid therapy (ACT) and size at birth: a population-based analysis using the Finnish Medical Birth Register</article-title><source>PLoS Med</source><year>2019</year><volume>16</volume><issue>2</issue><fpage>e1002746</fpage><pub-id pub-id-type="pmid">30807570</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Rodriguez A, Wang Y, Ali Khan A, Cartwright R, Gissler M, J&#x000e4;rvelin M-R. Antenatal corticosteroid therapy (ACT) and size at birth: a population-based analysis using the Finnish Medical Birth Register. PLoS Med. 2019;16(2): e1002746.<pub-id pub-id-type="pmid">30807570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>J</given-names></name><name><surname>Shennan</surname><given-names>A</given-names></name><name><surname>Jacobsson</surname><given-names>B</given-names></name><name><surname>Stock</surname><given-names>SJ</given-names></name></person-group><article-title>Birth FWGfP: FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm</article-title><source>Int J Gynaecol Obstet</source><year>2021</year><volume>155</volume><issue>1</issue><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">34520057</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Norman J, Shennan A, Jacobsson B, Stock SJ. Birth FWGfP: FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm. Int J Gynaecol Obstet. 2021;155(1):26&#x02013;30.<pub-id pub-id-type="pmid">34520057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Panel ACCPG: Antenatal corticosteroids given to women prior to birth to improve fetal, infant, child and adult health: Clinical Practice Guidelines. 2015.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><collab>Practice CoO</collab></person-group><article-title>Committee Opinion No. 713: antenatal corticosteroid therapy for fetal maturation</article-title><source>Obstet Gynecol</source><year>2017</year><volume>130</volume><issue>2</issue><fpage>e102</fpage><lpage>e109</lpage><pub-id pub-id-type="pmid">28742678</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Practice CoO. Committee Opinion No. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2017;130(2):e102&#x02013;9.<pub-id pub-id-type="pmid">28742678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">The C*STEROID Trial: Corticosteroids before planned caesarean section from 35+0 to 39+6 weeks of pregnancy. <ext-link ext-link-type="uri" xlink:href="https://cdn.auckland.ac.nz/assets/liggins/docs/CSTEROID_Protocol_V2_9Sept2020.pdf">https://cdn.auckland.ac.nz/assets/liggins/docs/CSTEROID_Protocol_V2_9Sept2020.pdf</ext-link>.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Oladapo</surname><given-names>OT</given-names></name><name><surname>Vogel</surname><given-names>JP</given-names></name><name><surname>Piaggio</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>MH</given-names></name><name><surname>Althabe</surname><given-names>F</given-names></name><name><surname>Bahl</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>SP</given-names></name><name><surname>De Costa</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Baqui</surname><given-names>AH</given-names></name></person-group><article-title>Effect of dexamethasone on newborn survival at different administration-to-birth intervals: a secondary analysis of the WHO ACTION (Antenatal CorticosTeroids for Improving Outcomes in Preterm Newborn)-I trial</article-title><source>EClinicalMedicine</source><year>2022</year><volume>53</volume><fpage>101744</fpage><pub-id pub-id-type="pmid">36467459</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Oladapo OT, Vogel JP, Piaggio G, Nguyen MH, Althabe F, Bahl R, Rao SP, De Costa A, Gupta S, Baqui AH. Effect of dexamethasone on newborn survival at different administration-to-birth intervals: a secondary analysis of the WHO ACTION (Antenatal CorticosTeroids for Improving Outcomes in Preterm Newborn)-I trial. EClinicalMedicine. 2022;53:101744.<pub-id pub-id-type="pmid">36467459</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Goldenberg</surname><given-names>RL</given-names></name><name><surname>Kemp</surname><given-names>MW</given-names></name></person-group><article-title>Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks</article-title><source>Am J Obstet Gynecol</source><year>2024</year><volume>230</volume><issue>3</issue><fpage>330</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">37734637</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jobe AH, Goldenberg RL, Kemp MW. Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks. Am J Obstet Gynecol. 2024;230(3):330&#x02013;9.<pub-id pub-id-type="pmid">37734637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Crowther</surname><given-names>C</given-names></name><name><surname>Middleton</surname><given-names>P</given-names></name><name><surname>Andersen</surname><given-names>C</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Doyle</surname><given-names>L</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name></person-group><article-title>Dexamethasone or betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability: the A* STEROID Trial</article-title><source>J Paediatr Child Health</source><year>2017</year><volume>53</volume><issue>Suppl 2</issue><fpage>22</fpage></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Crowther C, Middleton P, Andersen C, Ashwood P, Doyle L, Robinson J. Dexamethasone or betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability: the A* STEROID Trial. J Paediatr Child Health. 2017;53(Suppl 2):22.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>T</given-names></name><name><surname>Doret-Dion</surname><given-names>M</given-names></name><name><surname>Sentilhes</surname><given-names>L</given-names></name><name><surname>Parant</surname><given-names>O</given-names></name><name><surname>Claris</surname><given-names>O</given-names></name><name><surname>Renesme</surname><given-names>L</given-names></name><name><surname>Abbal</surname><given-names>J</given-names></name><name><surname>Girault</surname><given-names>A</given-names></name><name><surname>Torchin</surname><given-names>H</given-names></name><name><surname>Houllier</surname><given-names>M</given-names></name></person-group><article-title>Neonatal outcomes for women at risk of preterm delivery given half dose versus full dose of antenatal betamethasone: a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial</article-title><source>The Lancet</source><year>2022</year><volume>400</volume><issue>10352</issue><fpage>592</fpage><lpage>604</lpage></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Schmitz T, Doret-Dion M, Sentilhes L, Parant O, Claris O, Renesme L, Abbal J, Girault A, Torchin H, Houllier M. Neonatal outcomes for women at risk of preterm delivery given half dose versus full dose of antenatal betamethasone: a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial. The Lancet. 2022;400(10352):592&#x02013;604.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KE</given-names></name><name><surname>Hannah</surname><given-names>ME</given-names></name><name><surname>Willan</surname><given-names>AR</given-names></name><name><surname>Hewson</surname><given-names>SA</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>EN</given-names></name><name><surname>Matthews</surname><given-names>SG</given-names></name><name><surname>Saigal</surname><given-names>S</given-names></name><name><surname>Asztalos</surname><given-names>E</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name></person-group><article-title>Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial</article-title><source>The Lancet</source><year>2008</year><volume>372</volume><issue>9656</issue><fpage>2143</fpage><lpage>2151</lpage></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Murphy KE, Hannah ME, Willan AR, Hewson SA, Ohlsson A, Kelly EN, Matthews SG, Saigal S, Asztalos E, Ross S. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. The Lancet. 2008;372(9656):2143&#x02013;51.</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KE</given-names></name><name><surname>Willan</surname><given-names>AR</given-names></name><name><surname>Hannah</surname><given-names>ME</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>EN</given-names></name><name><surname>Matthews</surname><given-names>SG</given-names></name><name><surname>Saigal</surname><given-names>S</given-names></name><name><surname>Asztalos</surname><given-names>E</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name><name><surname>Delisle</surname><given-names>M-F</given-names></name></person-group><article-title>Effect of antenatal corticosteroids on fetal growth and gestational age at birth</article-title><source>Obstet Gynecol</source><year>2012</year><volume>119</volume><issue>5</issue><fpage>917</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">22525902</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Murphy KE, Willan AR, Hannah ME, Ohlsson A, Kelly EN, Matthews SG, Saigal S, Asztalos E, Ross S, Delisle M-F. Effect of antenatal corticosteroids on fetal growth and gestational age at birth. Obstet Gynecol. 2012;119(5):917&#x02013;23.<pub-id pub-id-type="pmid">22525902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000e4;ikk&#x000f6;nen</surname><given-names>K</given-names></name><name><surname>Gissler</surname><given-names>M</given-names></name><name><surname>Kajantie</surname><given-names>E</given-names></name></person-group><article-title>Associations between maternal antenatal corticosteroid treatment and mental and behavioral disorders in children</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>19</issue><fpage>1924</fpage><lpage>1933</lpage><pub-id pub-id-type="pmid">32427304</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">R&#x000e4;ikk&#x000f6;nen K, Gissler M, Kajantie E. Associations between maternal antenatal corticosteroid treatment and mental and behavioral disorders in children. JAMA. 2020;323(19):1924&#x02013;33.<pub-id pub-id-type="pmid">32427304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Lin YH, Lin CH, Lin MC, Hsu YC, Hsu CT. Antenatal corticosteroid exposure is associated with childhood mental disorders in late preterm and term infants. The Journal of Pediatrics. 2023;253:245-51.</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Ilg</surname><given-names>L</given-names></name><name><surname>Kirschbaum</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S-C</given-names></name><name><surname>Rosenl&#x000f6;cher</surname><given-names>F</given-names></name><name><surname>Miller</surname><given-names>R</given-names></name><name><surname>Alexander</surname><given-names>N</given-names></name></person-group><article-title>Persistent effects of antenatal synthetic glucocorticoids on endocrine stress reactivity from childhood to adolescence</article-title><source>J Clin Endocrinol Metab</source><year>2018</year><volume>104</volume><issue>3</issue><fpage>827</fpage><lpage>834</lpage></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Ilg L, Kirschbaum C, Li S-C, Rosenl&#x000f6;cher F, Miller R, Alexander N. Persistent effects of antenatal synthetic glucocorticoids on endocrine stress reactivity from childhood to adolescence. J Clin Endocrinol Metab. 2018;104(3):827&#x02013;34.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>N</given-names></name><name><surname>Rosenl&#x000f6;cher</surname><given-names>F</given-names></name><name><surname>Stalder</surname><given-names>T</given-names></name><name><surname>Linke</surname><given-names>J</given-names></name><name><surname>Distler</surname><given-names>W</given-names></name><name><surname>Morgner</surname><given-names>J</given-names></name><name><surname>Kirschbaum</surname><given-names>C</given-names></name></person-group><article-title>Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children</article-title><source>J Clin Endocrinol Metab</source><year>2012</year><volume>97</volume><issue>10</issue><fpage>3538</fpage><lpage>3544</lpage><pub-id pub-id-type="pmid">22869608</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Alexander N, Rosenl&#x000f6;cher F, Stalder T, Linke J, Distler W, Morgner J, Kirschbaum C. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. J Clin Endocrinol Metab. 2012;97(10):3538&#x02013;44.<pub-id pub-id-type="pmid">22869608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>FW</given-names></name><name><surname>Tsai</surname><given-names>HF</given-names></name><name><surname>Kuo</surname><given-names>PL</given-names></name><name><surname>Tsai</surname><given-names>PY</given-names></name></person-group><article-title>Antenatal corticosteroid therapy in late preterm delivery: a nationwide population-based retrospective study in Taiwan</article-title><source>BJOG An Int J Obstet Gynaecol</source><year>2021</year><volume>128</volume><issue>9</issue><fpage>1497</fpage><lpage>1502</lpage></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Liang FW, Tsai HF, Kuo PL, Tsai PY. Antenatal corticosteroid therapy in late preterm delivery: a nationwide population-based retrospective study in Taiwan. BJOG An Int J Obstet Gynaecol. 2021;128(9):1497&#x02013;502.</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>BA</given-names></name><name><surname>Lewandowski</surname><given-names>AJ</given-names></name><name><surname>Worton</surname><given-names>SA</given-names></name><name><surname>Davis</surname><given-names>EF</given-names></name><name><surname>Lazdam</surname><given-names>M</given-names></name><name><surname>Francis</surname><given-names>J</given-names></name><name><surname>Neubauer</surname><given-names>S</given-names></name><name><surname>Lucas</surname><given-names>A</given-names></name><name><surname>Singhal</surname><given-names>A</given-names></name><name><surname>Leeson</surname><given-names>P</given-names></name></person-group><article-title>Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism</article-title><source>Pediatrics</source><year>2012</year><volume>129</volume><issue>5</issue><fpage>e1282</fpage><lpage>e1290</lpage><pub-id pub-id-type="pmid">22508917</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kelly BA, Lewandowski AJ, Worton SA, Davis EF, Lazdam M, Francis J, Neubauer S, Lucas A, Singhal A, Leeson P. Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism. Pediatrics. 2012;129(5):e1282&#x02013;90.<pub-id pub-id-type="pmid">22508917</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Dalziel</surname><given-names>SR</given-names></name><name><surname>Walker</surname><given-names>NK</given-names></name><name><surname>Parag</surname><given-names>V</given-names></name><name><surname>Mantell</surname><given-names>C</given-names></name><name><surname>Rea</surname><given-names>HH</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Harding</surname><given-names>JE</given-names></name></person-group><article-title>Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial</article-title><source>The Lancet</source><year>2005</year><volume>365</volume><issue>9474</issue><fpage>1856</fpage><lpage>1862</lpage></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Dalziel SR, Walker NK, Parag V, Mantell C, Rea HH, Rodgers A, Harding JE. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. The Lancet. 2005;365(9474):1856&#x02013;62.</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Kemp</surname><given-names>MW</given-names></name></person-group><article-title>The complex challenge of antenatal steroid therapy non-responsiveness</article-title><source>Am J Obstet Gynecol</source><year>2022</year><volume>227</volume><issue>5</issue><fpage>697</fpage><lpage>704</lpage></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Takahashi T, Jobe AH, Fee EL, Newnham JP, Schmidt AF, Usuda H, Kemp MW. The complex challenge of antenatal steroid therapy non-responsiveness. Am J Obstet Gynecol. 2022;227(5):697&#x02013;704.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Yaegashi</surname><given-names>N</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Bridges</surname><given-names>JP</given-names></name><name><surname>Milad</surname><given-names>MA</given-names></name><name><surname>Furfaro</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>S</given-names></name></person-group><article-title>Continuous but not pulsed low-dose fetal betamethasone exposures extend the durability of antenatal steroid therapy</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2022</year><volume>322</volume><issue>6</issue><fpage>L784</fpage><lpage>L793</lpage><pub-id pub-id-type="pmid">35380907</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Takahashi T, Takahashi Y, Fee EL, Saito M, Yaegashi N, Usuda H, Bridges JP, Milad MA, Furfaro L, Carter S. Continuous but not pulsed low-dose fetal betamethasone exposures extend the durability of antenatal steroid therapy. Am J Physiol Lung Cell Mol Physiol. 2022;322(6):L784&#x02013;93.<pub-id pub-id-type="pmid">35380907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>SW</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Oguz</surname><given-names>G</given-names></name><name><surname>Ramasamy</surname><given-names>A</given-names></name><name><surname>Amin</surname><given-names>Z</given-names></name><name><surname>Agnihotri</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Xiawen</surname><given-names>L</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>Antenatal steroids elicited neurodegenerative-associated transcriptional changes in the hippocampus of preterm fetal sheep independent of lung maturation</article-title><source>BMC Med</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>338</fpage><pub-id pub-id-type="pmid">39183288</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Carter SW, Fee EL, Usuda H, Oguz G, Ramasamy A, Amin Z, Agnihotri B, Wei Q, Xiawen L, Takahashi T. Antenatal steroids elicited neurodegenerative-associated transcriptional changes in the hippocampus of preterm fetal sheep independent of lung maturation. BMC Med. 2024;22(1):338.<pub-id pub-id-type="pmid">39183288</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Carter</surname><given-names>S</given-names></name><name><surname>Furfaro</surname><given-names>L</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><name><surname>Milad</surname><given-names>MA</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Low-dose antenatal betamethasone treatment achieves preterm lung maturation equivalent to that of the World Health Organization dexamethasone regimen but with reduced endocrine disruption in a sheep model of pregnancy</article-title><source>Am J Obstet Gynecol</source><year>2022</year><volume>227</volume><issue>6</issue><fpage>903</fpage><lpage>e1</lpage></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Usuda H, Fee EL, Carter S, Furfaro L, Takahashi T, Takahashi Y, Newnham JP, Milad MA, Saito M, Jobe AH, et al. Low-dose antenatal betamethasone treatment achieves preterm lung maturation equivalent to that of the World Health Organization dexamethasone regimen but with reduced endocrine disruption in a sheep model of pregnancy. Am J Obstet Gynecol. 2022;227(6):903-e1.</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Carter</surname><given-names>S</given-names></name><name><surname>Furfaro</surname><given-names>L</given-names></name><name><surname>Clarke</surname><given-names>MW</given-names></name><name><surname>Milad</surname><given-names>MA</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name></person-group><article-title>One percent of the clinical dose used for antenatal steroid therapy is sufficient to induce lung maturation when administered directly to the preterm ovine fetus</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2022</year><volume>322</volume><issue>6</issue><fpage>L853</fpage><lpage>L865</lpage><pub-id pub-id-type="pmid">35438005</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Fee EL, Takahashi T, Takahashi Y, Carter S, Furfaro L, Clarke MW, Milad MA, Usuda H, Newnham JP, Saito M. One percent of the clinical dose used for antenatal steroid therapy is sufficient to induce lung maturation when administered directly to the preterm ovine fetus. Am J Physiol Lung Cell Mol Physiol. 2022;322(6):L853&#x02013;65.<pub-id pub-id-type="pmid">35438005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>SW</given-names></name><name><surname>Biswas</surname><given-names>A</given-names></name><name><surname>Watson</surname><given-names>HR</given-names></name><name><surname>Ip</surname><given-names>HLC</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Seah</surname><given-names>KYM</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Amin</surname><given-names>Z</given-names></name><name><surname>Choolani</surname><given-names>MA</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name></person-group><article-title>Addressing the long-term risks of administering antenatal steroids</article-title><source>Expert Opin Pharmacother</source><year>2025</year><volume>26</volume><issue>5</issue><fpage>617</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">40033629</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Carter SW, Biswas A, Watson HR, Ip HLC, Fee EL, Seah KYM, Kumagai Y, Amin Z, Choolani MA, Jobe AH. Addressing the long-term risks of administering antenatal steroids. Expert Opin Pharmacother. 2025;26(5):617&#x02013;29.<pub-id pub-id-type="pmid">40033629</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><name><surname>Moss</surname><given-names>TJ</given-names></name><name><surname>Ikegami</surname><given-names>M</given-names></name></person-group><article-title>Differential effects of maternal betamethasone and cortisol on lung maturation and growth in fetal sheep</article-title><source>Am J Obstet Gynecol</source><year>2003</year><volume>188</volume><issue>1</issue><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">12548191</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Jobe AH, Newnham JP, Moss TJ, Ikegami M. Differential effects of maternal betamethasone and cortisol on lung maturation and growth in fetal sheep. Am J Obstet Gynecol. 2003;188(1):22&#x02013;8.<pub-id pub-id-type="pmid">12548191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Pillow</surname><given-names>JJ</given-names></name><name><surname>Musk</surname><given-names>GC</given-names></name><name><surname>McLean</surname><given-names>CM</given-names></name><name><surname>Polglase</surname><given-names>GR</given-names></name><name><surname>Dalton</surname><given-names>RGB</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Suki</surname><given-names>B</given-names></name></person-group><article-title>Variable ventilation improves ventilation and lung compliance in preterm lambs</article-title><source>Intensive Care Med</source><year>2011</year><volume>37</volume><issue>8</issue><fpage>1352</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">21567115</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Pillow JJ, Musk GC, McLean CM, Polglase GR, Dalton RGB, Jobe AH, Suki B. Variable ventilation improves ventilation and lung compliance in preterm lambs. Intensive Care Med. 2011;37(8):1352&#x02013;9.<pub-id pub-id-type="pmid">21567115</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Ikegami</surname><given-names>M</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Newnham</surname><given-names>J</given-names></name><name><surname>Polk</surname><given-names>DH</given-names></name><name><surname>Willet</surname><given-names>KE</given-names></name><name><surname>Sly</surname><given-names>P</given-names></name></person-group><article-title>Repetitive prenatal glucocorticoids improve lung function and decrease growth in preterm lambs</article-title><source>Am J Respir Crit Care Med</source><year>1997</year><volume>156</volume><issue>1</issue><fpage>178</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">9230744</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ikegami M, Jobe AH, Newnham J, Polk DH, Willet KE, Sly P. Repetitive prenatal glucocorticoids improve lung function and decrease growth in preterm lambs. Am J Respir Crit Care Med. 1997;156(1):178&#x02013;84.<pub-id pub-id-type="pmid">9230744</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Carter</surname><given-names>SWD</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Clarke</surname><given-names>MW</given-names></name><name><surname>Ireland</surname><given-names>DJ</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Single-nucleotide polymorphisms in dizygotic twin ovine fetuses are associated with discordant responses to antenatal steroid therapy</article-title><source>BMC Med</source><year>2025</year><volume>23</volume><issue>1</issue><fpage>65</fpage><pub-id pub-id-type="pmid">39901164</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Fee EL, Usuda H, Carter SWD, Ikeda H, Takahashi T, Takahashi Y, Kumagai Y, Clarke MW, Ireland DJ, Newnham JP, et al. Single-nucleotide polymorphisms in dizygotic twin ovine fetuses are associated with discordant responses to antenatal steroid therapy. BMC Med. 2025;23(1):65.<pub-id pub-id-type="pmid">39901164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Kemp</surname><given-names>MW</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Molloy</surname><given-names>TJ</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><name><surname>Fossler</surname><given-names>M</given-names></name><name><surname>Scmidt</surname><given-names>A</given-names></name></person-group><article-title>Maternofetal pharmacokinetics and fetal lung responses in chronically catheterized sheep receiving constant, low-dose infusions of betamethasone phosphate</article-title><source>Am J Obstet Gynecol</source><year>2016</year><volume>215</volume><issue>6</issue><fpage>775. e771</fpage><lpage>775. e712</lpage></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kemp MW, Saito M, Usuda H, Molloy TJ, Miura Y, Sato S, Watanabe S, Clarke M, Fossler M, Scmidt A. Maternofetal pharmacokinetics and fetal lung responses in chronically catheterized sheep receiving constant, low-dose infusions of betamethasone phosphate. Am J Obstet Gynecol. 2016;215(6):775. e771-775. e712.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Kemp</surname><given-names>MW</given-names></name><name><surname>Rittenschober-B&#x000f6;hm</surname><given-names>J</given-names></name><name><surname>Kannan</surname><given-names>PS</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Furfaro</surname><given-names>L</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Stock</surname><given-names>S</given-names></name><name><surname>Kramer</surname><given-names>BW</given-names></name></person-group><article-title>Low-dose betamethasone-acetate for fetal lung maturation in preterm sheep</article-title><source>Am J Obstet Gynecol</source><year>2018</year><volume>218</volume><issue>1</issue><fpage>132. e131</fpage><lpage>132. e139</lpage></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Schmidt AF, Kemp MW, Rittenschober-B&#x000f6;hm J, Kannan PS, Usuda H, Saito M, Furfaro L, Watanabe S, Stock S, Kramer BW. Low-dose betamethasone-acetate for fetal lung maturation in preterm sheep. Am J Obstet Gynecol. 2018;218(1):132. e131-132. e139.</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Hanita</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Koshinami</surname><given-names>S</given-names></name></person-group><article-title>Variability in the efficacy of a standardized antenatal steroid treatment was independent of maternal or fetal plasma drug levels: evidence from a sheep model of pregnancy</article-title><source>Am J Obstet Gynecol</source><year>2020</year><volume>223</volume><issue>6</issue><fpage>921. e921</fpage><lpage>921. e910</lpage></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Takahashi T, Saito M, Schmidt AF, Usuda H, Takahashi Y, Watanabe S, Hanita T, Sato S, Kumagai Y, Koshinami S. Variability in the efficacy of a standardized antenatal steroid treatment was independent of maternal or fetal plasma drug levels: evidence from a sheep model of pregnancy. Am J Obstet Gynecol. 2020;223(6):921. e921-921. e910.</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Milad</surname><given-names>MA</given-names></name><name><surname>Peppard</surname><given-names>T</given-names></name><name><surname>Jusko</surname><given-names>WJ</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of intramuscular and oral betamethasone and dexamethasone in reproductive age women in India</article-title><source>Clin Transl Sci</source><year>2020</year><volume>13</volume><issue>2</issue><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">31808984</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Jobe AH, Milad MA, Peppard T, Jusko WJ. Pharmacokinetics and pharmacodynamics of intramuscular and oral betamethasone and dexamethasone in reproductive age women in India. Clin Transl Sci. 2020;13(2):391&#x02013;9.<pub-id pub-id-type="pmid">31808984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Kannan</surname><given-names>PS</given-names></name><name><surname>Bridges</surname><given-names>JP</given-names></name><name><surname>Filuta</surname><given-names>A</given-names></name><name><surname>Lipps</surname><given-names>D</given-names></name><name><surname>Kemp</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>LA</given-names></name><name><surname>Kallapur</surname><given-names>SG</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><article-title>Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>9039</fpage><pub-id pub-id-type="pmid">31227752</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Schmidt AF, Kannan PS, Bridges JP, Filuta A, Lipps D, Kemp M, Miller LA, Kallapur SG, Xu Y, Whitsett JA. Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques. Sci Rep. 2019;9(1):9039.<pub-id pub-id-type="pmid">31227752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Kemp</surname><given-names>MW</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Hanita</surname><given-names>T</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Molloy</surname><given-names>TJ</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><name><surname>Eddershaw</surname><given-names>PJ</given-names></name></person-group><article-title>The efficacy of antenatal steroid therapy is dependent on the duration of low-concentration fetal exposure: evidence from a sheep model of pregnancy</article-title><source>Am J Obstet Gynecol</source><year>2018</year><volume>219</volume><issue>3</issue><fpage>301. e301</fpage><lpage>301. e316</lpage></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kemp MW, Saito M, Usuda H, Watanabe S, Sato S, Hanita T, Kumagai Y, Molloy TJ, Clarke M, Eddershaw PJ. The efficacy of antenatal steroid therapy is dependent on the duration of low-concentration fetal exposure: evidence from a sheep model of pregnancy. Am J Obstet Gynecol. 2018;219(3):301. e301-301. e316.</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Kemp</surname><given-names>MW</given-names></name><name><surname>Milad</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>LA</given-names></name><name><surname>Bridges</surname><given-names>JP</given-names></name><name><surname>Clarke</surname><given-names>MW</given-names></name><name><surname>Kannan</surname><given-names>PS</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name></person-group><article-title>Oral dosing for antenatal corticosteroids in the Rhesus macaque</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><issue>9</issue><fpage>e0222817</fpage><pub-id pub-id-type="pmid">31536601</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Schmidt AF, Kemp MW, Milad M, Miller LA, Bridges JP, Clarke MW, Kannan PS, Jobe AH. Oral dosing for antenatal corticosteroids in the Rhesus macaque. PLoS ONE. 2019;14(9): e0222817.<pub-id pub-id-type="pmid">31536601</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Crowther</surname><given-names>CA</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Andersen</surname><given-names>CC</given-names></name><name><surname>Middleton</surname><given-names>PF</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>Doyle</surname><given-names>LW</given-names></name><name><surname>Robinson</surname><given-names>JS</given-names></name><name><surname>Harding</surname><given-names>JE</given-names></name><name><surname>Crowther</surname><given-names>C</given-names></name><name><surname>Andersen</surname><given-names>C</given-names></name></person-group><article-title>Maternal intramuscular dexamethasone versus betamethasone before preterm birth (ASTEROID): a multicentre, double-blind, randomised controlled trial</article-title><source>Lancet Child Adolesc Health</source><year>2019</year><volume>3</volume><issue>11</issue><fpage>769</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">31523039</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Crowther CA, Ashwood P, Andersen CC, Middleton PF, Tran T, Doyle LW, Robinson JS, Harding JE, Crowther C, Andersen C. Maternal intramuscular dexamethasone versus betamethasone before preterm birth (ASTEROID): a multicentre, double-blind, randomised controlled trial. Lancet Child Adolesc Health. 2019;3(11):769&#x02013;80.<pub-id pub-id-type="pmid">31523039</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Baryakova</surname><given-names>TH</given-names></name><name><surname>Pogostin</surname><given-names>BH</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name><name><surname>McHugh</surname><given-names>KJ</given-names></name></person-group><article-title>Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems</article-title><source>Nat Rev Drug Discovery</source><year>2023</year><volume>22</volume><issue>5</issue><fpage>387</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">36973491</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discovery. 2023;22(5):387&#x02013;409.<pub-id pub-id-type="pmid">36973491</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Kemp</surname><given-names>MW</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><name><surname>Challis</surname><given-names>J</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Stock</surname><given-names>S</given-names></name></person-group><article-title>The clinical use of corticosteroids in pregnancy</article-title><source>Hum Reprod Update</source><year>2016</year><volume>22</volume><issue>2</issue><fpage>240</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">26590298</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Kemp MW, Newnham JP, Challis J, Jobe AH, Stock S. The clinical use of corticosteroids in pregnancy. Hum Reprod Update. 2016;22(2):240&#x02013;59.<pub-id pub-id-type="pmid">26590298</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoes</surname><given-names>JN</given-names></name><name><surname>Jacobs</surname><given-names>JWG</given-names></name><name><surname>Boers</surname><given-names>M</given-names></name><name><surname>Boumpas</surname><given-names>D</given-names></name><name><surname>Buttgereit</surname><given-names>F</given-names></name><name><surname>Caeyers</surname><given-names>N</given-names></name><name><surname>Choy</surname><given-names>EH</given-names></name><name><surname>Cutolo</surname><given-names>M</given-names></name><name><surname>Da Silva</surname><given-names>JAP</given-names></name><name><surname>Esselens</surname><given-names>G</given-names></name><etal/></person-group><article-title>EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><issue>12</issue><fpage>1560</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">17660219</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Hoes JN, Jacobs JWG, Boers M, Boumpas D, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JAP, Esselens G, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560&#x02013;7.<pub-id pub-id-type="pmid">17660219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Shehata</surname><given-names>N</given-names></name><name><surname>Ye</surname><given-names>XY</given-names></name><name><surname>Gregorovich</surname><given-names>S</given-names></name><name><surname>De France</surname><given-names>B</given-names></name><name><surname>Arnold</surname><given-names>DM</given-names></name><name><surname>Shah</surname><given-names>PS</given-names></name><name><surname>Malinowski</surname><given-names>AK</given-names></name></person-group><article-title>Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy</article-title><source>Blood J Am Soc Hematol</source><year>2016</year><volume>128</volume><issue>10</issue><fpage>1329</fpage><lpage>1335</lpage></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Sun D, Shehata N, Ye XY, Gregorovich S, De France B, Arnold DM, Shah PS, Malinowski AK. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood J Am Soc Hematol. 2016;128(10):1329&#x02013;35.</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Varner</surname><given-names>M</given-names></name></person-group><article-title>Myasthenia gravis and pregnancy</article-title><source>Clin Obstet Gynecol</source><year>2013</year><volume>56</volume><issue>2</issue><fpage>372</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">23563874</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Varner M. Myasthenia gravis and pregnancy. Clin Obstet Gynecol. 2013;56(2):372&#x02013;81.<pub-id pub-id-type="pmid">23563874</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Torday</surname><given-names>JS</given-names></name><name><surname>Nielsen</surname><given-names>HC</given-names></name><name><surname>Fencl</surname><given-names>MDM</given-names></name><name><surname>Avery</surname><given-names>ME</given-names></name></person-group><article-title>Sex differences in fetal lung maturation</article-title><source>Am Rev Respir Dis</source><year>1981</year><volume>123</volume><issue>2</issue><fpage>205</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">6894519</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Torday JS, Nielsen HC, Fencl MDM, Avery ME. Sex differences in fetal lung maturation. Am Rev Respir Dis. 1981;123(2):205&#x02013;8.<pub-id pub-id-type="pmid">6894519</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Ishak</surname><given-names>N</given-names></name><name><surname>Sozo</surname><given-names>F</given-names></name><name><surname>Harding</surname><given-names>R</given-names></name><name><surname>De Matteo</surname><given-names>R</given-names></name></person-group><article-title>Does lung development differ in male and female fetuses?</article-title><source>Exp Lung Res</source><year>2014</year><volume>40</volume><issue>1</issue><fpage>30</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">24354441</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ishak N, Sozo F, Harding R, De Matteo R. Does lung development differ in male and female fetuses? Exp Lung Res. 2014;40(1):30&#x02013;9.<pub-id pub-id-type="pmid">24354441</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>PL</given-names></name><name><surname>Ballard</surname><given-names>RA</given-names></name><name><surname>Granberg</surname><given-names>JP</given-names></name><name><surname>Sniderman</surname><given-names>S</given-names></name><name><surname>Gluckman</surname><given-names>PD</given-names></name><name><surname>Kaplan</surname><given-names>SL</given-names></name><name><surname>Grumbach</surname><given-names>MM</given-names></name></person-group><article-title>Fetal sex and prenatal betamethasone therapy</article-title><source>J Pediatr</source><year>1980</year><volume>97</volume><issue>3</issue><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">7411310</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Ballard PL, Ballard RA, Granberg JP, Sniderman S, Gluckman PD, Kaplan SL, Grumbach MM. Fetal sex and prenatal betamethasone therapy. J Pediatr. 1980;97(3):451&#x02013;4.<pub-id pub-id-type="pmid">7411310</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>AGB</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Crowther</surname><given-names>CA</given-names></name><name><surname>Gamble</surname><given-names>GD</given-names></name><name><surname>Dalziel</surname><given-names>SR</given-names></name><name><surname>Harding</surname><given-names>JE</given-names></name></person-group><article-title>Betamethasone for preterm birth: Auckland steroid trial full results and new insights 50 years on</article-title><source>J Pediatr</source><year>2023</year><volume>255</volume><fpage>80</fpage><lpage>88.e85</lpage><pub-id pub-id-type="pmid">36336005</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Walters AGB, Lin L, Crowther CA, Gamble GD, Dalziel SR, Harding JE. Betamethasone for preterm birth: Auckland steroid trial full results and new insights 50 years on. J Pediatr. 2023;255:80-88.e85.<pub-id pub-id-type="pmid">36336005</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>